NovaBridge Biosciences (NBP) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Voyager Therapeutics (VYGR) has outperformed NovaBridge Biosciences (NBP) over the past year, losing 61.6% versus a loss of 78.2%. Over five years, VYGR leads with a -49.9% price change compared with -98.1% for NBP. NovaBridge Biosciences is the larger company by market cap ($146.2 million vs $117.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBP | VYGR |
|---|---|---|
| Share price | $1.26 | $1.90 |
| Market cap | $146.16M | $117.07M |
| 1-day change | -2.33% | -7.77% |
| YTD return | -68.34% | -51.65% |
| 1-year return | -78.16% | -61.62% |
| 5-year return | -98.13% | -49.87% |
| EPS (TTM) | $-0.69 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | $-46.27M | $-119.72M |
| Operating margin | — | -326.56% |
| Net margin | — | -296.53% |
| 52-week high | $5.97 | $5.48 |
| 52-week low | $1.26 | $1.89 |
| Distance from 52-week high | -78.89% | -65.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +614.29% | +683.68% |
| Average volume | 390.05K | 578.54K |
| Shares outstanding | 116.00M | 61.62M |
| Employees | 30 | 141 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VYGR has outperformed NBP by 16.5 percentage points over the past year.
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Healthcare · Biotechnology · 141 employees
NBP vs VYGR FAQ
Which is bigger, NovaBridge Biosciences or Voyager Therapeutics?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $146.16M compared with $117.07M for Voyager Therapeutics (VYGR).
Which stock has performed better over the past year, NBP or VYGR?
VYGR returned -61.62% over the past 12 months, compared with -78.16% for NBP (price return, excluding dividends). Past performance does not predict future results.
Are NovaBridge Biosciences and Voyager Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.